The prostatic specific antigen (PSA) is the most important tumor marker in screening and follow up of prostate
cancer. Its elevations in plasma can be atributed to either benign or malignant diseases. In the past few years, the determinations of is free plasmatic fraction has increased his specificity in the detection of early prostatic cancer. We analize and confront the international experience with free PSA and the results of its implementation at the Universíty of Chile Clinical Hospital.
Valdevenito, R. ., Valdevenito S., J. P. ., López M., M. ., Frías J, J. C. ., & Rodrigo S., C. . (1999). Utilidad del Antígeno Prostático. Revista Hospital Clínico Universidad De Chile, 10(3), pp. 189–94. https://doi.org/10.5354/2735-7996.1999.80614
